Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Alison Kukulka is active.

Publication


Featured researches published by Alison Kukulka.


Journal of Medicinal Chemistry | 2009

Structure-Based Optimization of Arylamides as Inhibitors of Soluble Epoxide Hydrolase

Anne B. Eldrup; Fariba Soleymanzadeh; Steven John Taylor; Ingo Muegge; Neil A. Farrow; David B. Joseph; Keith McKellop; Chuk Chui Man; Alison Kukulka; Stéphane De Lombaert

Inhibition of soluble epoxide hydrolase (sEH) is hypothesized to lead to an increase in circulating levels of epoxyeicosatrienoic acids, resulting in the potentiation of their in vivo pharmacological properties. As part of an effort to identify inhibitors of sEH with high and sustained plasma exposure, we recently performed a high throughput screen of our compound collection. The screen identified N-(3,3-diphenyl-propyl)-nicotinamide as a potent inhibitor of sEH. Further profiling of this lead revealed short metabolic half-lives in microsomes and rapid clearance in the rat. Consistent with these observations, the determination of the in vitro metabolic profile of N-(3,3-diphenyl-propyl)-nicotinamide in rat liver microsomes revealed extensive oxidative metabolism and a propensity for metabolite switching. Lead optimization, guided by the analysis of the solid-state costructure of N-(3,3-diphenyl-propyl)-nicotinamide bound to human sEH, led to the identification of a class of potent and selective inhibitors. An inhibitor from this class displayed an attractive in vitro metabolic profile and high and sustained plasma exposure in the rat after oral administration.


Journal of Medicinal Chemistry | 2010

Nonsteroidal Dissociated Glucocorticoid Agonists Containing Azaindoles as Steroid A-Ring Mimetics

Doris Riether; Christian Harcken; Hossein Razavi; Daniel Kuzmich; Thomas A. Gilmore; Jörg Bentzien; Edward J. Pack; Donald Souza; Richard M. Nelson; Alison Kukulka; Tazmeen N. Fadra; Ljiljana Zuvela-Jelaska; Josephine Pelletier; Roger M. Dinallo; Mark Panzenbeck; Carol Torcellini; Gerald H. Nabozny; David S. Thomson

Syntheses and structure-activity relationships (SAR) of nonsteroidal glucocorticoid receptor (GR) agonists are described. These compounds contain azaindole moieties as A-ring mimetics and display various degrees of in vitro dissociation between gene transrepression and transactivation. Collagen induced arthritis studies in mouse have demonstrated that in vitro dissociated compounds (R)-16 and (R)-37 have steroid-like anti-inflammatory properties with improved metabolic side effect profiles, such as a reduced increase in body fat and serum insulin levels, compared to steroids.


Bioorganic & Medicinal Chemistry Letters | 2010

Substituted pyrazoles as novel sEH antagonist: investigation of key binding interactions within the catalytic domain.

Ho Yin Lo; Chuk Chui Man; Roman Wolfgang Fleck; Neil A. Farrow; Richard H. Ingraham; Alison Kukulka; John R. Proudfoot; Raj Betageri; Tom Kirrane; Usha R. Patel; Rajiv Sharma; Mary Ann Hoermann; Alisa Kabcenell; Stephane De Lombaert

A novel series of pyrazole sEH inhibitors is reported. Lead optimization efforts to replace the aniline core are also described. In particular, 2-pyridine, 3-pyridine and pyridazine analogs are potent sEH inhibitors with favorable CYP3A4 inhibitory and microsomal stability profiles.


Bioorganic & Medicinal Chemistry Letters | 2010

Optimization of piperidyl-ureas as inhibitors of soluble epoxide hydrolase.

Anne Bettina Eldrup; Fariba Soleymanzadeh; Neil A. Farrow; Alison Kukulka; Stephane De Lombaert

Inhibition of sEH is hypothesized to lead to an increase in epoxyeicosatrienoic acids resulting in the potentiation of their anti-inflammatory and vasodilatory effects. In an effort to explore sEH inhibition as an avenue for the development of vasodilatory and cardio- or renal-protective agents, a lead identified through high-throughput screening was optimized, guided by the determination of a solid state co-structure with sEH. Replacement of potential toxicophores was followed by optimization of cell-based potency and ADME properties to provide a new class of functionally potent sEH inhibitors with attractive in vitro metabolic profiles and high and sustained plasma exposures after oral administration in the rat.


Bioorganic & Medicinal Chemistry Letters | 2009

Design and synthesis of substituted nicotinamides as inhibitors of soluble epoxide hydrolase

Steven John Taylor; Fariba Soleymanzadeh; Anne Bettina Eldrup; Neil A. Farrow; Ingo Muegge; Alison Kukulka; Alisa Kabcenell; Stephane De Lombaert

A series of potent nicotinamide inhibitors of soluble epoxides hydrolase (sEH) is disclosed. This series was designed using structure-based deconstruction and a combination of two HTS hit series, resulting in hybrid analogs that retained the optimal potency from one series, and acceptable in vitro metabolic stability from the other. Structure-guided optimization of these analogs gave rise to nanomolar inhibitors of human sEH that had acceptable plasma exposure to qualify them as probes to determine the in vivo phenotypic consequences of sEH inhibition.


Bioorganic & Medicinal Chemistry Letters | 2011

Non-steroidal dissociated glucocorticoid agonists: indoles as A-ring mimetics and function-regulating pharmacophores

Raj Betageri; Thomas A. Gilmore; Daniel Kuzmich; Thomas M. Kirrane; Jörg Bentzien; Dieter Wiedenmayer; Younes Bekkali; John R. Regan; Angela Berry; Bachir Latli; Alison Kukulka; Tazmeen N. Fadra; Richard M. Nelson; Susan E. Goldrick; Ljiljana Zuvela-Jelaska; Don Souza; Josephine Pelletier; Roger M. Dinallo; Mark Panzenbeck; Carol Torcellini; Heewon Lee; Edward Pack; Christian Harcken; Gerald Nabozny; David S. Thomson

We report a SAR of non-steroidal glucocorticoid mimetics that utilize indoles as A-ring mimetics. Detailed SAR is discussed with a focus on improving PR and MR selectivity, GR agonism, and in vitro dissociation profile. SAR analysis led to compound (R)-33 which showed high PR and MR selectivity, potent agonist activity, and reduced transactivation activity in the MMTV and aromatase assays. The compound is equipotent to prednisolone in the LPS-TNF model of inflammation. In mouse CIA, at 30 mg/kg compound (R)-33 inhibited disease progression with an efficacy similar to the 3 mg/kg dose of prednisolone.


Bioorganic & Medicinal Chemistry Letters | 2010

Rapid synthesis of an array of trisubstituted urea-based soluble epoxide hydrolase inhibitors facilitated by a novel solid-phase method

Jennifer A. Kowalski; Alan David Swinamer; Ingo Muegge; Anne Bettina Eldrup; Alison Kukulka; Charles L. Cywin; Stephane De Lombaert

A 270-membered library of trisubstituted ureas was synthesized and evaluated for inhibition of soluble epoxide hydrolase. Library design and reagent selection was guided by the use of a pharmacophore model and synthesis of the array was enabled with a general solid-phase method. This array approach facilitated multi-dimensional SAR around this series and identified functionality responsible for binding affinity, as well as opportunities for modulating the overall in vitro profiles of this class of soluble epoxide hydrolase inhibitors.


Bioorganic & Medicinal Chemistry Letters | 2014

Discovery of a potent and dissociated non-steroidal glucocorticoid receptor agonist containing an alkyl carbinol pharmacophore.

Hossein Razavi; Doris Riether; Christian Harcken; Jörg Bentzien; Roger M. Dinallo; Donald Souza; Richard M. Nelson; Alison Kukulka; Tazmeen Fadra-Khan; Edward J. Pack; Ljiljana Zuvela-Jelaska; Josephine Pelletier; Mark Panzenbeck; Carol Torcellini; John R. Proudfoot; Gerald Nabozny; David S. Thomson

Synthesis and structure-activity relationship (SAR) of a series of alkyl and cycloalkyl containing non-steroidal dissociated glucocorticoid receptor (GR) agonists is reported. This series of compounds was identified as part of an effort to replace the CF3 group in a scaffold represented by 1a. The study culminated in the identification of compound 14, a t-butyl containing derivative, which has shown potent activity for GR, selectivity against the progesterone receptor (PR) and the mineralocorticoid receptor (MR), in vitro anti-inflammatory activity in an IL-6 transrepression assay, and dissociation in a MMTV transactivation counter-screen. In a collagen-induced arthritis mouse model, 14 displayed prednisolone-like efficacy, and lower impact on body fat and free fatty acids than prednisolone at an equivalent anti-inflammatory dose.


Bioorganic & Medicinal Chemistry Letters | 2013

Function-regulating pharmacophores in a sulfonamide class of glucocorticoid receptor agonists

Daniel Kuzmich; Jörg Bentzien; Raj Betageri; Darren Disalvo; Tazmeen Fadra-Khan; Christian Harcken; Alison Kukulka; Gerald Nabozny; Richard M. Nelson; Edward Pack; Donald Souza; David S. Thomson

A class of α-methyltryptamine sulfonamide glucocorticoid receptor (GR) modulators was optimized for agonist activity. The design of ligands was aided by molecular modeling, and key function-regulating pharmacophoric points were identified that are critical in achieving the desired agonist effect in cell based assays. Compound 27 was profiled in vitro and in vivo in models of inflammation. Analogs could be rapidly prepared in a parallel approach from aziridine building blocks.


Bioorganic & Medicinal Chemistry Letters | 2013

Substituted phenyl as a steroid A-ring mimetic: Providing agonist activity to a class of arylsulfonamide nonsteroidal glucocorticoid ligands

Darren Disalvo; Daniel Kuzmich; Jörg Bentzien; John R. Regan; Alison Kukulka; Tazmeen Fadra-Khan; Richard M. Nelson; Christian Harcken; David S. Thomson; Gerald Nabozny

A class of arylsulfonamide glucocorticoid receptor agonists that contains a substituted phenyl group as a steroid A-ring mimetic is reported. The structural design and SAR that provide the functional switching of a GR antagonist to an agonist is described. A combination of specific hydrogen bonding and lipophilic elements on the A-ring moiety is required to achieve potent GR agonist activity. This study culminated in the identification of compound 23 as a potent GR agonist with selectivity over the PR and MR nuclear hormone receptors.

Collaboration


Dive into the Alison Kukulka's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge